Neoadjuvant in Situ and Systemic Immunotherapy with Lymph Node Cryoablation in Resectable Stage III Melanoma Metastasis: a Proof-of-Concept Study
ConclusionCombining percutaneous cryotherapy with in situ ipilimumab and systemic nivolumab for stage III resectable melanoma is feasible with tolerable toxicity.Graphical Abstract (Source: CardioVascular and Interventional Radiology)
Source: CardioVascular and Interventional Radiology - April 3, 2024 Category: Radiology Source Type: research
Ipilimumab/Pembrolizumab
(Source: Reactions Weekly)
Source: Reactions Weekly - April 1, 2024 Category: Drugs & Pharmacology Source Type: research
218 A case of Toxic Epidermal Necrolysis secondary to combination Ipilimumab and Nivolumab therapy for Pleural Mesothelioma, successfully treated with Ruxolitinib
We present the case of a patient who developed Toxic Epidermal Necrolysis (TEN) as the primary feature of a multi-system autoimmune syndrome following combination ipilimumab and nivolumab for mesothelioma, successfully treated with Ruxolitinib. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Judy Tabbakh, Racha Kussaibati, Francesca Kinsella, Gary Middleton, Victoria Kunene, Sawsan Elsheikh, Claudia Roberts, Darren Lewis, Rachel Powell, Ser-Ling Chua, Shobhit Baijal Tags: Case Reports Source Type: research
75 Real world toxicity data for the use of ipilimumab plus nivolumab in malignant mesothelioma
Ipilimumab plus nivolumab has been licensed to treat malignant mesothelioma (MM) in England since 2020. Here we present the real world toxicity outcomes for MM patients receiving this first line doublet immunotherapy regimen at a single UK centre. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: McGrath Harriet, Kaiser Anam, Cienne Morton, Spyridon Gennatas, Sharmistha Ghosh, Eleni Karapanagiotou, Alexandras Georgiou, James Spicer Tags: Mesothelioma Source Type: research
73 Ipilimumab and Nivolumab for mesothelioma: a real-world UK tertiary centre experience
Ipilimumab and Nivolumab (IPI/NIVO) has been reimbursed as 1st line treatment for patients with mesothelioma in the UK since July 2022 based on the CHECKMATE 743 study, which demonstrated survival benefit of IPI/NIVO over chemotherapy, largely driven by improvement in non-epithelioid subgroup. Toxicity profile was consistent with use of this regimen in other malignancies. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: David John McMahon, Trisha Patel, Rehab Ahmed, Alexius John, Elizabeth Cartwright, Thubeena Manickavasagar, Charlotte Milner-Watts, Abu Taher, Cheryl Estall, Nadia Yousaf, Sanjay Popat, Mary O Brien, Michael Davidson, Jaishree Bhosle, Anna Minchom, Nadza Tags: Mesothelioma Source Type: research
66 Early Experiences of the Use of Combination Immunotherapy for the Treatment of Malignant Mesothelioma from 2022 –2023 – Real-World Evidence of 1-Year Data from a Single UK Tertiary Cancer Centre
The landscape of systemic anticancer therapy (SACT) options for the treatment of malignant mesothelioma recently evolved following results from the CheckMate 743 trial which demonstrated improved overall survival in patients with malignant pleural mesothelioma receiving combination immunotherapy (Ipilimumab/ Nivolumab) in the first-line setting. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Justin KH Liu, Stephanie R Harrison, Dan Lee Tags: Mesothelioma Source Type: research
63 Real-world outcomes of Nivlolumab-Ipilimumab combination therapy in unresectable malignant mesothelioma: Mount Vernon Cancer Centre Experience
We report real-world toxicity and outcomes from several hospitals within our Trust. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Tabitha Achim, Mujtaba Ehsan, Karen Henderson, Thalia Afxentiou, Vikash Dodhia, Wendy Ng, Ridwan Ahmed, Andreas Polychronis, Geirgios Antoniou, Ernese Xhafa-Hamati, Arshi Denton, Suzannah Mawdsley, Jeanette Dickson, Suprotim Basu, Suraiya Dubash Tags: Mesothelioma Source Type: research
62 Single-centre DGH experience of using immunotherapy for malignant mesothelioma
The treatment options for mesothelioma has expanded with the availability of immune checkpoint inhibitors; 2nd line Nivolumab in 2020 (interim COVID NICE guidance) and 1st line Ipilimumab& Nivolumab in 2022. This audit provides an overview of our initial experience with these drugs for mesothelioma. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Dan Patterson, Katie Ball Tags: Mesothelioma Source Type: research
60 First-line Nivolumab/Ipilimumab in patients with unresectable malignant pleural Mesothelioma (MPM): West of Scotland experience
We present our local experience of patients with MPM treated with Ipilimumab plus Nivolumab. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Aitzaz Qaisar, Mark White, Nicola Steele Tags: Mesothelioma Source Type: research
59 Immunotherapy Toxicities in Real-World Use of Nivolumab & Ipilimumab in Pleural Malignant Mesothelioma: Experience from Sussex Cancer Centre
Data from Checkmate 743 (CM743) study has established Nivolumab/ Ipilimumab (N/I) combination immunotherapy as the first line palliative treatment for Malignant Pleural Mesothelioma (MPM). Since July 2022, N/I have been available on the NHS via the Cancer Drug Fund. We retrospectively assessed the toxicity profile in MPM patients who received N/I as first line palliative treatment. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Cheung Lonn, Kam Zaki, Victoria Donovan, Kavita Kanlal Tags: Mesothelioma Source Type: research
Literature review Analysis of the Current State of Targeted Therapy for Gastrointestinal Cancers
This article provided a clinical summary of the most recent advances in targeted treatment for GEC and the supporting clinical data, such as their efficacy and safety profiles.PMID:38551425 (Source: Alternative Therapies in Health and Medicine)
Source: Alternative Therapies in Health and Medicine - March 29, 2024 Category: Complementary Medicine Authors: Xinge Miao Chenxing Jin Xiang Ji Yibin Teng Jiwei Liu Source Type: research
Literature review Analysis of the Current State of Targeted Therapy for Gastrointestinal Cancers
This article provided a clinical summary of the most recent advances in targeted treatment for GEC and the supporting clinical data, such as their efficacy and safety profiles.PMID:38551425 (Source: Alternative Therapies in Health and Medicine)
Source: Alternative Therapies in Health and Medicine - March 29, 2024 Category: Complementary Medicine Authors: Xinge Miao Chenxing Jin Xiang Ji Yibin Teng Jiwei Liu Source Type: research
Literature review Analysis of the Current State of Targeted Therapy for Gastrointestinal Cancers
This article provided a clinical summary of the most recent advances in targeted treatment for GEC and the supporting clinical data, such as their efficacy and safety profiles.PMID:38551425 (Source: Alternative Therapies in Health and Medicine)
Source: Alternative Therapies in Health and Medicine - March 29, 2024 Category: Complementary Medicine Authors: Xinge Miao Chenxing Jin Xiang Ji Yibin Teng Jiwei Liu Source Type: research
Literature review Analysis of the Current State of Targeted Therapy for Gastrointestinal Cancers
This article provided a clinical summary of the most recent advances in targeted treatment for GEC and the supporting clinical data, such as their efficacy and safety profiles.PMID:38551425 (Source: Alternative Therapies in Health and Medicine)
Source: Alternative Therapies in Health and Medicine - March 29, 2024 Category: Complementary Medicine Authors: Xinge Miao Chenxing Jin Xiang Ji Yibin Teng Jiwei Liu Source Type: research
Literature review Analysis of the Current State of Targeted Therapy for Gastrointestinal Cancers
This article provided a clinical summary of the most recent advances in targeted treatment for GEC and the supporting clinical data, such as their efficacy and safety profiles.PMID:38551425 (Source: Alternative Therapies in Health and Medicine)
Source: Alternative Therapies in Health and Medicine - March 29, 2024 Category: Complementary Medicine Authors: Xinge Miao Chenxing Jin Xiang Ji Yibin Teng Jiwei Liu Source Type: research
